Login / Signup

Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia.

Arlene ChanChristopher LommaHuiJun ChihElizabeth BlackelyNatasha WoodwardDaphne TsoiKerry CheongMitchell ChipmanAndrew Redfern
Published in: Asia-Pacific journal of clinical oncology (2021)
Similar efficacy was demonstrated for eribulin when given in the first-line to beyond the fifth line of chemotherapy in all subtypes of MBC.
Keyphrases
  • metastatic breast cancer
  • squamous cell carcinoma
  • small cell lung cancer
  • phase ii
  • locally advanced
  • clinical trial
  • combination therapy
  • replacement therapy
  • study protocol